摘要
目的 探讨前列腺特异抗原诊断前列腺癌的临床应用价值。方法 采用酶联免疫方法分别测定了 41例前列腺癌 ,3 6例前列腺增生血清前列腺特异性抗原 ,游离前列腺特异抗原含量 ,并计算出f -PSA/t -PSA的比率 ,同时测定了前列腺体积。结果 t -PSA在 4 0～ 10 0 μg/L范围时 ,t -PSA的平均值在前列腺癌组 ,前列腺增生组之间无显著性差异 ;f-PSA/t -PSA比率在前列腺癌组织中显著降低 ;同时f-PSA/t -PSA比率和前列腺体积在前列腺癌组中呈正相关 ,在前列腺增生组中无相关性。结论 f-PSA/t -PSA比率在前列腺体积小于 40cm× 40cm×
Objective To study the clinical value of prostate specific antigen(PSA) in diagnosing prostate cancer(PCa).Methods f-PSA and t-PSA in 41 cases of PCa and 36 cases of benigen prostate hyperplasia (BPH) were measured. Prostate volume was determined by transrectal ultrasound. Results In patients with t-PSA between 4.0～10.0 μg/L,medians of t-PSA were not significantly different between men with prostate cancer and men with BPH. Diffences in median percentages of free PSA for these two groups were statisticales significant( P <0.05). In PCa patients, a significant positive correlation(r=0.268, P <0.05) was found beween f-PSA% and prostate volume, whereas there was no significant correlations in BPH patients(r=0.216, P <0.05). Conclusions Determining the ratio of f-PSA to t-PSA was a useful tumor marker for PCa only in men with a prostate volume of less than 40cm×40cm×40cm.
出处
《河南肿瘤学杂志》
2002年第3期178-179,共2页
Henan Journal of Oncology
关键词
前列腺特异抗原
诊断
前列腺癌
临床应用
酶联免疫法
prostate carcinoma
total prostate specific antigen
free prostate specific antigen
prostate volume
